N-MYC impairs innate immune signaling in high-grade serous ovarian carcinoma
Science Advances · 17.05.2024 · 10 (20)
DOI: 10.1126/sciadv.adj5428 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 17.05.2024. Verfasst von Alex Miranda und 12 weiteren Autor:innen. Beteiligte Einrichtung: Deeley Research Centre, BC Cancer, Victoria, BC V8R 6V5, Canada. Hauptthemen laut MEDLINE: Immunity, Innate, Ovarian Neoplasms, Signal Transduction, N-Myc Proto-Oncogene Protein. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS.
Abstract (Originalsprache)
High-grade serous ovarian cancer (HGSC) is a challenging disease, especially for patients with immunologically “cold” tumors devoid of tumor-infiltrating lymphocytes (TILs). We found that HGSC exhibits among the highest levels of MYCN expression and transcriptional signature across human cancers, which is strongly linked to diminished features of antitumor immunity. N-MYC repressed basal and induced IFN type I signaling in HGSC cell lines, leading to decreased chemokine expression and T cell chemoattraction. N-MYC inhibited the induction of IFN type I by suppressing tumor cell–intrinsic STING signaling via reduced STING oligomerization, and by blunting RIG-I–like receptor signaling through inhibition of MAVS aggregation and localization in the mitochondria. Single-cell RNA sequencing of human clinical HGSC samples revealed a strong negative association between cancer cell–intrinsic MYCN transcriptional program and type I IFN signaling. Thus, N-MYC inhibits tumor cell–intrinsic innate immune signaling in HGSC, making it a compelling target for immunotherapy of cold tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Deeley Research Centre, BC Cancer, Victoria, BC V8R 6V5, Canada.
- Department of Medical Genetics, University of British Columbia, Vancouver, BC V6T 1Z3, Canada.
- The Kinghorn Cancer Centre and Cancer Division, Garvan Institute of Medical Research, 370 Victoria St, Darlinghurst, NSW, Australia.
- Department of Biochemistry and Microbiology, University of Victoria, Victoria, BC V8P 3E6, Canada.
- Nuclear Dynamics and Cancer Program, Fox Chase Cancer Center, Philadelphia, PA, USA.
- Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
ORCID-Profile: Alex Miranda, Swetansu Pattnaik, Monica Alvaro Fuss, Shreena Kalaria, Céline M Laumont, Allyson Banville, Xinpei Jiang, Russell Jenkins, Israel Cañadas, Brad H Nelson
Förderung
- NIGMS NIH HHS
Zitieren
APA
Miranda, A., Pattnaik, S., Hamilton, P. T., Fuss, M. A., Kalaria, S., Laumont, C. M., Smazynski, J., Mesa, M., Banville, A., Jiang, X., Jenkins, R., Cañadas, I., & Nelson, B. H. (2024). N-MYC impairs innate immune signaling in high-grade serous ovarian carcinoma. Science Advances, 10(20). https://doi.org/10.1126/sciadv.adj5428
Vancouver
Miranda A, Pattnaik S, Hamilton PT, Fuss MA, Kalaria S, Laumont CM, et al. N-MYC impairs innate immune signaling in high-grade serous ovarian carcinoma. Science Advances. 2024;10(20). doi:10.1126/sciadv.adj5428
BibTeX
@article{Miranda2024,
author = {Miranda, Alex and Pattnaik, Swetansu and Hamilton, Phineas T and Fuss, Monica Alvaro and Kalaria, Shreena and Laumont, Céline M and Smazynski, Julian and Mesa, Monica and Banville, Allyson and Jiang, Xinpei and Jenkins, Russell and Cañadas, Israel and Nelson, Brad H},
title = {N-MYC impairs innate immune signaling in high-grade serous ovarian carcinoma},
journal = {Science Advances},
year = {2024},
volume = {10},
number = {20},
doi = {10.1126/sciadv.adj5428}
}
EUVIMED